A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2017
At a glance
- Drugs Octreotide (Primary) ; Cabergoline; Lanreotide
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms MPOWERED
- Sponsors Chiasma
- 10 Jun 2017 Biomarkers information updated
- 19 May 2017 This trial has been suspended Netherlands as per European Clinical Trials Database record.
- 15 Sep 2016 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.